Page last updated: 2024-10-24

positive regulation of opsonization

Definition

Target type: biologicalprocess

Any process that activates or increases the frequency, rate or extent of opsonization. [GO_REF:0000058, GOC:BHF, GOC:rl, GOC:TermGenie, PMID:22333221]

Opsonization is a crucial process in the innate immune system that enhances the phagocytosis of pathogens by immune cells. Positive regulation of opsonization refers to mechanisms that amplify or promote this process. Here's a detailed description:

**1. Opsonins:**

* Opsonins are molecules that bind to the surface of pathogens, marking them as targets for phagocytosis. These molecules include:
* **Antibodies (Immunoglobulins):** These proteins are produced by B cells in response to specific antigens on pathogens. Antibodies bind to antigens via their variable regions, and their constant regions can bind to receptors on phagocytes.
* **Complement Proteins:** The complement system is a cascade of proteins that activate upon recognition of pathogen surfaces. Complement activation results in the deposition of opsonizing proteins like C3b on the pathogen's surface.
* **Collectins:** These are soluble pattern recognition receptors that bind to carbohydrates on pathogens. They can directly interact with phagocytes or act as bridging molecules between pathogens and complement proteins.

**2. Phagocytes:**

* Phagocytes are immune cells that engulf and destroy pathogens. Key phagocytic cells include neutrophils, macrophages, and dendritic cells. They express receptors that bind to opsonins.
* **Fc Receptors:** These receptors recognize the constant region of antibodies bound to pathogens.
* **Complement Receptors:** These receptors bind to complement proteins deposited on the pathogen surface.

**3. Enhanced Phagocytosis:**

* The binding of opsonins to the pathogen's surface creates a bridge between the pathogen and the phagocyte.
* This interaction triggers:
* **Increased phagocytic activity:** Phagocytes are stimulated to engulf the opsonized pathogen more efficiently.
* **Signal transduction:** The binding of opsonins to their receptors activates signaling pathways within the phagocyte, leading to the release of antimicrobial molecules and the activation of other immune responses.
* **Improved Pathogen Recognition:** Opsonization can also enhance the recognition of pathogens by phagocytes, particularly when pathogens are poorly recognized by the immune system alone.

**4. Positive Regulation Mechanisms:**

* **Cytokine Production:** Cytokines like interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α) can promote opsonization by:
* Increasing the expression of complement proteins.
* Stimulating the production of antibodies.
* Enhancing the activity of phagocytes.
* **Complement Activation:** The activation of the complement system can be enhanced by factors like:
* **C-reactive protein:** A soluble protein produced by the liver that binds to pathogens and activates the complement pathway.
* **Mannose-binding lectin:** A lectin that binds to mannose residues on pathogens, initiating complement activation.
* **Antibody Production:** The production of antibodies specific to pathogen antigens is a critical component of the adaptive immune response. This response is regulated by T helper cells, which release cytokines that stimulate B cell proliferation and antibody production.

**In conclusion, positive regulation of opsonization involves a complex interplay of various factors that enhance the recognition and engulfment of pathogens by phagocytes. This crucial process is essential for the effective clearance of pathogens and the maintenance of immune homeostasis.'
"

Proteins (1)

ProteinDefinitionTaxonomy
Phospholipase A2 group VA phospholipase A2 group V that is encoded in the genome of human. [PRO:DNx, UniProtKB:P39877]Homo sapiens (human)

Compounds (4)

CompoundDefinitionClassesRoles
3-octylthio-1,1,1-trifluoro-2-propanone3-octylthio-1,1,1-trifluoro-2-propanone: a pesticide synergist; inhibits juvenile hormone esterase
varespladibaromatic ether;
benzenes;
dicarboxylic acid monoamide;
indoles;
monocarboxylic acid;
primary carboxamide
anti-inflammatory drug;
antidote;
EC 3.1.1.4 (phospholipase A2) inhibitor
ym 26734YM 26734: inhibits group II phospholipase A2; structure given in first source
indoxamindoxam: structure in first source